Insulin-like growth factor binding proteins (IGFBPs) comprise a family of proteins that bind and regulate the functions of IGFs. One of the IGFBPs, IGFBP2, has recently been shown to be overexpressed in glioblastoma. Overexpression of IGFBP2 contributes to the invasiveness of glioblastoma and correlates with histologic grade and survival in patients with diffuse gliomas, suggesting that IGFBP2 expression may contribute to the glioma formation and/or progression. The expression of other IGFBP family members in gliomas has, however, not been examined in detail. This study was designed to evaluate the expression of IGFBP3 and IGFBP5 in diffuse gliomas using immunohistochemistry applied to a tissue array constructed from 259 gliomas, including ten gliosarcomas. Expression of IGFBP5 correlated significantly with glioma histologic grade. 83% (58/70) of glioblastomas (WHO Grade IV) were positive for IGFBP5, which was significantly higher than WHO Grade III gliomas (41%, 41/101) or WHO Grade II gliomas (18%, 13/72) (p<0.001). In contrast, IGFBP3 was expressed in 17%, 23%, and 17% of WHO Grade IV, Grade III, and Grade II gliomas, respectively (p>0.05). There was no significant difference in IGFBP3 expression among different grades of glioma. Our study thus demonstrates that the expression of IGFBP5, but not IGFBP3, increases with glioma anaplastic progression. The strong correlation between overexpression of IGFBP5 and histologic grade suggests that, in addition to IGFBP2, IGFBP5 may also play a role in glioma progression.
Introduction
Diffuse gliomas are the most common intracranial neoplasms and account for more than 60% of all primary brain tumors (1). Diffuse gliomas are separated by grade into Grade II (low-grade glioma), Grade III (anaplastic glioma), and Grade IV (glioblastoma multiforme) by the World Health Organization (WHO) 2000 Classification of Brain Tumors (1). Significant differences exist in patient survival among the different histological grades of diffuse gliomas, with a typical median survival of more than five years for grade II gliomas, two to five years for grade III, and less than one year for grade IV (2-4).
The insulin-like growth factors (IGF-I and IGF-II) stimulate cell proliferation in a variety of tissues and cell lines. Human gliomas produce IGFs and express elevated levels of IGF receptors compared with normal brain tissue (5) (6) (7) (8) . Treatment of glioblastoma cell spheroids with IGF-I dramatically enhances three dimensional tumor growth, suggesting that IGFs enhance glioblastoma cell proliferation when three dimensional cell-cell contact occurs (9) . The functions of IGF are regulated by IGF binding proteins (IGFBPs), which are composed of a family of six structurally homologous proteins, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, and IGFBP6 (10, 11) . IGFBPs bind IGFs with high affinity and regulate the effects of IGFs on the target cells (10, 11). In 1999, Fuller et al. first reported that IGFBP2 is consistently overexpressed only in the highest grade of glioma, glioblastoma, using a cDNA microarray gene expression profiling approach (12). We and other groups subsequently confirmed the differential overex-Figure 1: Glioma tissue microarray comprising of 249 diffuse gliomas and ten gliosarcomas, plus normal brain and cell line controls (each specimen sampled in duplicate with two 0.6 mm tissue cores, A). B: Glioma TMA map of the paraffin tissue microarray block shown in panel A and the H&E-stained tissue section prepared from the microarray block shown in panel C. Abbreviations: AA, Anaplastic astrocytoma; AO, Anaplastic oligodendroglioma; AMOA, Anaplastic mixed oligoastrocytoma; CL, Cell line controls; GM, Glioblastoma multiforme; GS, Gliosarcoma; LGA, Low grade diffuse astrocytoma; MOA, Mixed oligoastrocytoma; NB, Normal brain; O, Oligodendroglioma. pression of IGFBP2 in glioblastoma using high-throughput glioma tissue microarrays (13, 14) . IGFBP2 overexpression has been shown to be associated with tumor progression and poor survival in patients with diffuse gliomas (13). More recent studies have shown that overexpression of IGFBP2 may contribute to the invasiveness of glioblastoma. Stable SNB19 GBM cell lines that overexpress IGFBP2 show significantly increased rates of invasion compared to the controls. IGFBP2 overexpression leads to the up-regulation of matrix metalloproteinase 2 (MMP-2) in GBM cell lines (15) . Furthermore, overexpression of IGFBP2 correlates significantly with increased MMP-2 expression in human GBM tumor samples (15). These data suggest that IGFBP2 expression contributes to glioma progression in part by enhancing MMP-2 gene expression, which in turn increases tumor cell invasion capability. The expression of other IGFBP family members has also been reported in the brain and in brain tumors (16, 17) . Their expression and the role in diffuse gliomas has, however, not been examined in detail. The present study evaluates the expression of IGFBP3 and IGFBP5 in diffuse gliomas using high-density tissue microarrays combined with immunohistochemistry.
Materials and Methods

Selection of Diffuse Glioma Samples and Construction of Glioma Tissue Microarray
The glioma samples were obtained from patients who underwent surgery from 1986 to 2001. Formalin-fixed, paraffinembedded tissue blocks, and corresponding H&E-stained slides were retrieved from the archive. The slides were reviewed, classified, and graded by a neuropathologist following the diagnostic criteria set forth in the WHO 2000 classification, and screened for representative tumor regions. A glioma tissue microarray was constructed from tissue cores extracted from the formalin-fixed, paraffin-embedded archival tissue blocks with a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI) as described previously (14, 18) . The tissue array included 259 primary gliomas with all histologic subtypes and grades of diffuse gliomas codified in the WHO 2000 classification represented, including 70 glioblastomas (GBM), 49 anaplastic astrocytomas (AA), nine low-grade astrocytomas (LGA), 41 anaplastic oligodendrogliomas (AO), 41 low-grade oligodendrogliomas (O), 15 anaplastic mixed oligoastrocytomas (AMOA), 24 mixed oligoastrocytomas (MOA), and ten gliosarcomas (GS). In addition, ten normal brain samples and 16 cultured cell lines (ten GBM cell lines, two breast cancer cell lines, two squamous cell carcinoma cell lines, one colon cancer cell line, and one fetal kidney cell line) were also included, some of which were genetically engineered or treated with cytokines to serve as negative or positive controls. Each tumor was sampled in duplicate from representative areas of either one or two donor blocks with 0.6 mm diameter punch cores. The glioma tissue microarray, a microarray map, and a representative H&E-stained tissue section prepared from the microarray are shown in Figure 1 .
Immunohistochemistry and Statistical Analysis
Immunohistochemistry was performed using polyclonal antibodies directed against IGFBP3 and IGFBP5 (Santa Cruz Biotechnology, Inc., CA). Theses antibodies are type-specific and there is no cross reaction between the two antibodies and other IGFBP isoforms. A standard indirect immunoperoxidase procedure (ABC-Elite; Vector Laboratories, Burlingame, CA) was used for all immunohistochemical stains. In brief, antigen retrieval was performed by treatment of the unstained slides in a steamer for 25 min. Antibody directed against IGFBP3 (1:500 dilution) or IGFBP5 (1:500 dilution) was applied to the glioma TMA tissue sections and incubated at 4 ºC overnight. Secondary antibody incubation was performed at room temperature for 60 min. Mayer's hematoxylin nuclear staining was used as a counterstain. The results of IGFBP3 and IGFBP5 immunohistochemistry were evaluated by two pathologists and placed into two categories. The positive category represented strong immunoreaction in 10% or more of the tumor cells in at least one of the two duplicate tissue cores for each tumor specimen, and the negative category represented very weak or absent staining, or less than 10% strongly positive tumor cells in both of the duplicate cores. The immunophenotypic results were analyzed using the Chi-square test or Fisher's exact test.
Results
Immunohistochemical staining for IGFBP3 and for IGFBP5 was technically successful in 97.3% (252/259) and 97.7% (253/259), respectively, of the glioma tissue samples in tissue microarray. Representative photomicrographs showing H&E and immunohistochemical stains for IGFBP3 and IGFBP5 in normal brain and the different histologic subtypes of glioma are shown in Figure 2 and Figure 3 . In normal brain, weak cytoplasmic staining for IGFBP3 and moderate cytoplasmic staining for IGFBP5 was detected in neurons ( Figure 2, C and E) . The astrocytes and oligodendrocytes in normal brain were negative for both markers in all of the ten normal brain samples examined (Figure 2 , C and E). In gliomas that were positive for either IGFBP3 or IGFBP5, however, tumor cells showed strong diffuse cytoplasmic staining for IGFBP3 or IGFBP5 (Figure 2 and Figure 3 ).
The positivity rates for IGFBP5 in gliomas of different histologic subtypes are shown in between GBMs and AAs, GBMs and LGAs, and AAs and
LGAs, were statistically significant (p<0.05). In the oligoand the mixed oligoastrocytic tumors, the overexpression of IGFBP5 was also significantly lower compared to GBM (p<0.05, Table I and Figure 4 ). IGFBP5 was overexpressed in 16/40 (40%) of AOs and 6/15 (40%) of AMOAs, as compared to 8/40 (20%) in Os and 5/24 (21%) in MOAs. The WHO grade III oligodendroglial and oligoastrocytic tumors (AO & AMOA) had a significantly higher positivity rate (40%, 22/55) for IGFBP5 expression than the WHO grade II oligodendroglial or oligoastrocytic tumors (20%, 13/65, p=0.026, Figure  4 ). However, no significant differences in IGFBP5 expression were observed among AAs, AOs and AMOAs, or among
LGAs, Os, and MOAs. IGFBP5 was also strongly expressed in seven of ten gliosarcomas examined (70%, 7/10). IGFBP5 expression was not observed in astrocytes and oligodendrocytes in any of the normal cerebral or cerebellar brain tissue samples included in the microarray. In summary, IGFBP5 expression correlates significantly with increasing histologic grade in diffuse gliomas (Table I and Figure 4) .
In contrast, positive immunohistochemical staining for IGFBP3 was observed only in 12/70 (17%), 7/47 (15%), and 0/9 (0%) of GBMs, AAs, and LGAs, respectively. There was no significant difference in IGFBP3 expression among different grades of astrocytic tumors (p>0.05, Table I and Figure 4 ). Similar results for IGFBP3 expression were also observed in the oligodendroglial and mixed oligoastrocytic series. The positive rates for IGFBP3 were 30% (12/40) and 29% (4/14) in AOs and AMOAs, respectively, compared to those in Os (18%, 7/39) and MOAs (22%, 5/23). The difference in IGFBP3 expression between the WHO grade III and grade II oligodendroglial and oligoastrocytic tumors was not statistically significant (p>0.05, Table I and Figure 4) . Therefore, our data does not show a significant correlation between the expression of IGFBP3 and the histologic grade of diffuse gliomas. Interestingly, eight of the ten gliosarcomas examined were positive for IGFBP3, which was signifi-cantly higher compared to GBM (17%, 12/70). The differential expression of IGFBP3 in GS compared to GBM may suggest different molecular alterations in GS and GBM.
Discussion
Tissue microarray technology is an exciting and powerful new tool that has rapidly been adopted and customized in many laboratories for a large number of uses, including research laboratory applications, clinical laboratory applications, and educational forum applications (14). Tissue microarrays are composite paraffin blocks constructed by extracting cylindrical tissue core biopsies from individual donor paraffin blocks and re-embedding these into the recipient (microarray) block at precisely defined and ordered array coordinates (14, 18) . Using this technique, up to 1,000 or more individual tissue samples can be composited into a single paraffin block. Consecutive TMA tissue section analysis permits direct comparison of alterations of multiple molecular targets in virtually identical, histologically highly conserved tumor regions, and thereby facilitates rapid molecular dissection of oncogenetic regulatory pathways and correlation with significant clinically relevant parameters such as tumor histologic grade, tumor progression, and patient survival. Tumor heterogeneity with respect to study marker expression constitutes a potential problem for tissue microarray-based studies, particularly in the case of GBM, which is well recognized for its morphologic and immunophenotypic heterogeneity. The relative representativity of tissue microarray-based studies, however, has been extensively examined for a number of markers, and the data published so far clearly indicate that the frequencies of molecular alterations identified by high-throughput tissue microarray screening analysis generally correspond well with those identified using full-size tissue sections (14). For example, good agreement among immunohistochemical staining results for p53 protein in diffuse gliomas has also been shown by comparing full-size tissue section to tissue microarray analysis using single 0.6-mm cores (13). In the present study, we selected representative areas after screening H&E-stained tissue sections from all available blocks for each tumor and incorporated two tissue cores from each glioma sample into the microarray. In addition, we included normal brain tissue cores and cytospin cores of genetically altered cell lines and cytokine-treated cell lines into the array specifically to serve as positive and negative controls for the markers under study. These controls help to ensure reliability of interpretation of the immunophenotypic data.
IGFs stimulate cell proliferation in an autocrine fashion in many tumors and have been demonstrated to enhance glioblastoma cell proliferation in a three dimensional spheroid model (9). Recent findings demonstrate that IGFBP2 is differentially overexpressed in glioblastomas and contributes to poor survival, tumor progression, and glioblastoma cell invasion (12-15). These data further support the role of the IGF pathway in glioma progression. Using tissue microarrays and immunohistochemistry, we examined the expression of two additional members of the IGFBP family, IGFBP3 and IGFBP5, in 259 gliomas. We found that IGFBP5 was overexpressed in 83% of GBMs (WHO grade IV), 41% of WHO grade III gliomas, and 18% of WHO grade II gliomas (p<0.05, Figure 4 ). IGFBP5 was also overexpressed in 70% of GSs examined. In contrast, IGFBP3 was overexpressed in only 17%, 23%, and 17% of WHO grade IV, grade III, and grade II gliomas, respectively (Figure 4 ). There were no statistical differences in IGFBP3 expression among the different grades of gliomas (p<0.05). This is consistent with our previous observation from cDNA microarray analysis studies, which also showed no significant differences in IGFBP3 expression in primary gliomas of different grades (data not shown). Both IGFBP3 and IGFBP5 were not expressed in the astrocytes or oligodendrocytes of normal brain cortex and cerebellum.
Therefore, our study demonstrates that the expression of IGFBP5, but not IGFBP3, increases with glioma progression. The strong correlation between overexpression of IGFBP5 and histologic grade suggests that, in addition to IGFBP2, IGFBP5 may also play a role in glioma progression. IGFBP3 was overexpressed in 80% of GS, which is significantly higher compared to that observed in GBM (17%). The differential expression of IGFBP3 in GS may reflect different molecular alterations involved in the formation of GS and GBM.
